pioglitazone has been researched along with Cerebral Infarction in 10 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Present study was carried out to investigate the possible neuroprotective effect of pioglitazone, an antidiabetic agent, peroxisome proliferator-activated receptor gamma (PPARgamma) agonist on acute phase changes in mice model of cerebral ischemia induced by Bilateral Common Carotid artery Occlusion (BCCAO)." | 7.76 | Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice. ( Aggarwal, R; Chakrabarti, A; Medhi, B, 2010) |
| "The role of the phosphorylated signal transducer and activator of transcription-3 (p-STAT3) after cerebral ischemia by the peroxisome proliferator-activated receptor γ (PPARγ) agonist pioglitazone (PGZ) remains controversial." | 3.78 | Activation of signal transducer and activator of transcription-3 by a peroxisome proliferator-activated receptor gamma agonist contributes to neuroprotection in the peri-infarct region after ischemia in oophorectomized rats. ( Kageji, T; Kinouchi, T; Kitazato, KT; Matsushita, N; Nagahiro, S; Satomi, J; Shimada, K; Sumiyoshi, M; Tada, Y; Yagi, K, 2012) |
| "Present study was carried out to investigate the possible neuroprotective effect of pioglitazone, an antidiabetic agent, peroxisome proliferator-activated receptor gamma (PPARgamma) agonist on acute phase changes in mice model of cerebral ischemia induced by Bilateral Common Carotid artery Occlusion (BCCAO)." | 3.76 | Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice. ( Aggarwal, R; Chakrabarti, A; Medhi, B, 2010) |
| "Pre-treatment with fenofibrate and pioglitazone in addition to their combination improved neurobehavioral dysfunction, reduced cerebral infarct volume, attenuated inflammatory and apoptotic markers and ameliorated histopathological changes in I/R injured rats." | 1.56 | The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion. ( Abdelrehim, AB; Ahmed, AF; Heeba, GH; Shehata, AHF, 2020) |
| "Pioglitazone or vehicle was infused intracerebroventricularly over a 5-day period before, during and 24 or 48 h after middle cerebral artery occlusion." | 1.36 | Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. ( Culman, J; Glatz, T; Gohlke, P; Herdegen, T; Nguyen-Ngoc, M; Stöck, I; Zhao, Y, 2010) |
| "Pioglitazone treatment reduced the infarct size and improved neurological functions." | 1.35 | Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. ( Culman, J; Gohlke, P; Herdegen, T; Patzer, A; Stöck, I; Zhao, Y, 2008) |
| "Rosiglitazone treatment curtailed the post-ischemic expression of the pro-inflammatory genes interleukin-1beta, interleukin-6, macrophage inflammatory protein-1alpha, monocyte chemoattractant protein-1, cyclooxygenase-2, inducible nitric oxide synthase, early growth response-1, CCAAT/enhancer binding protein-beta and nuclear factor-kappa B, and increased the expression of the anti-oxidant enzymes catalase and copper/zinc-superoxide dismutase." | 1.34 | Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. ( Bowen, KK; Feinstein, DL; Kapadia, R; Liang, J; Satriotomo, I; Tureyen, K; Vemuganti, R, 2007) |
| "Pioglitazone or vehicle were i." | 1.33 | The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. ( Culman, J; Gohlke, P; Herdegen, T; Patzer, A; Zhao, Y, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shehata, AHF | 1 |
| Ahmed, AF | 1 |
| Abdelrehim, AB | 1 |
| Heeba, GH | 1 |
| Patzer, A | 2 |
| Zhao, Y | 3 |
| Stöck, I | 2 |
| Gohlke, P | 3 |
| Herdegen, T | 3 |
| Culman, J | 3 |
| Lee, SR | 1 |
| Kim, HY | 1 |
| Hong, JS | 1 |
| Baek, WK | 1 |
| Park, JW | 1 |
| Glatz, T | 1 |
| Nguyen-Ngoc, M | 1 |
| Medhi, B | 1 |
| Aggarwal, R | 1 |
| Chakrabarti, A | 1 |
| Blankenship, D | 1 |
| Niemi, J | 1 |
| Hilow, E | 1 |
| Karl, M | 1 |
| Sundararajan, S | 1 |
| Kinouchi, T | 1 |
| Kitazato, KT | 1 |
| Shimada, K | 1 |
| Yagi, K | 1 |
| Tada, Y | 1 |
| Matsushita, N | 1 |
| Sumiyoshi, M | 1 |
| Satomi, J | 1 |
| Kageji, T | 1 |
| Nagahiro, S | 1 |
| Tureyen, K | 1 |
| Kapadia, R | 1 |
| Bowen, KK | 1 |
| Satriotomo, I | 1 |
| Liang, J | 1 |
| Feinstein, DL | 1 |
| Vemuganti, R | 1 |
10 other studies available for pioglitazone and Cerebral Infarction
| Article | Year |
|---|---|
The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion.
Topics: Animals; Apoptosis; Brain; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Drug Therapy | 2020 |
Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Ence | 2008 |
PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Cytoprotection; Male; Matrix Metalloproteinase Inhibit | 2009 |
Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain.
Topics: Animals; Brain; Brain Ischemia; Cerebral Infarction; Infarction, Middle Cerebral Artery; Interleukin | 2010 |
Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischemia in mice.
Topics: Acute-Phase Reaction; Animals; Antioxidants; Brain Edema; Brain Ischemia; Carotid Artery, Common; Ce | 2010 |
Oral pioglitazone reduces infarction volume and improves neurologic function following MCAO in rats.
Topics: Administration, Oral; Animals; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Hypoglyc | 2011 |
Activation of signal transducer and activator of transcription-3 by a peroxisome proliferator-activated receptor gamma agonist contributes to neuroprotection in the peri-infarct region after ischemia in oophorectomized rats.
Topics: Animals; Apoptosis; Basal Ganglia; Brain; Brain Ischemia; Caspase 3; Cell Nucleus; Cerebral Infarcti | 2012 |
The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain.
Topics: Animals; Brain; Brain Edema; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Encephalit | 2005 |
[New subgroup analysis of the PROactive Study. Risk for recurrent stroke cut in half].
Topics: Cerebral Infarction; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Hum | 2006 |
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
Topics: Anilides; Animals; Cerebral Infarction; Chemotaxis, Leukocyte; Cytokines; Diabetes Mellitus, Type 2; | 2007 |